Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: Liquid dosage forms of Aprepitant are not much explored. The present invention describes ready to use, oral liquid compositions of Aprepitant suitable for the patients having swallowing difficulties. The liquid compositions of the present invention are storage stable for prolonged time and can be used for the prevention and control of acute and delayed chemotherapy induced nausea and vomiting, and for the prevention of postoperative nausea and vomiting.

Abstract: The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Abstract: Cinacalcet is approved and marketed as hydrochloride salt in a solid dosage form indicated for the treatment of secondary hyperparathyroidism resulting from chronic kidney disease and for the treatment of hypercalcemia in patients with either parathyroid carcinoma or hyperparathyroidism. Current marketed products are not allowed to be divided and to be taken whole during administration. Patients having swallowing difficulty may not show adherence to such regimen. The present invention therefore provides liquid dosage forms of Cinacalcet or pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: The present invention provides pharmaceutical composition of immunosuppressive agent in oral suspension dosage form. The oral suspension composition comprises of immunosuppressive agent with other pharmaceutical excipients such as vehicle, suspending agent, solvent or cosolvent, preservative, sweetener, antifoaming agent, wetting agent, buffering agent and flavouring agent. The present invention oral suspension having improved stability, palatability with high dose of active ingredient. The present invention provides oral suspension with flavor that has masked bitter taste of the drug and eliminates difficulty of administration. Further, the present invention also provides a convenient, easy process for preparation thereof.

Abstract: Imatinib is approved and marketed in solid oral dosage forms which may be dispersed in water or apple juice for patients having swallowing difficulty. Dispersion of Imatinib solid dosage forms in apple juice may increase palatability and patient compliance but apple juice may not be available all the time for administration. Further, dispersion of Imatinib solid oral dosage forms may not administer correct and consistent dose of medicine every time. The present invention therefore provides liquid dosage forms of Imatinib which correctly and consistently administers correct dose of drug to the patients.

Abstract: Pre-mixed, ready-to-use injectable compositions possess certain advantages such as convenience and ease of use as compared to an ampule formulation, improved safety for patients due to elimination of dosage errors and solution contamination, reduction of medical waste, and ease of administration in emergency situations. Pre-mixed, ready-to-use Vancomycin injectable preparations though marketed have numbers of disadvantages which makes its handling and use difficult. The present invention therefore provides pre-mixed, ready-to-use injectable formulations of Vancomycin which eliminates disadvantages and difficulties of the marketed product and at the same time maintains desired stability for prolonged time.

Abstract: The present invention provides pharmaceutical composition of antineoplastic alkylating agent in oral suspension dosage form. The oral suspension composition comprises of alkylating agent with other pharmaceutical excipients such as vehicle, preservative, antioxidant, suspending agent, surfactant, sweetener and flavouring agent. The present invention is an oral suspension having improved stability and palatability. The present invention also provides oral solution with flavor that has masked bitter taste of the drug. Further, the present invention also provides a process for preparation thereof.

Abstract: The present invention discloses a processes for the preparation of a stable liquid pharmaceutical composition comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients wherein the liquid composition of the present invention is used for oral administration. The present invention also discloses stable liquid compositions comprising levothyroxine or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients prepared according to the processes of the present invention.

Abstract: The present invention provides pharmaceutical composition of muscarinic antagonist in oral solution dosage form. The oral solution composition comprises of muscarinic antagonist with other pharmaceutical excipients such as vehicle, preservative, buffering agent, sweetener and flavouring agent. The present invention is an oral solution of muscarinic antagonist that is free from allergic preservatives and having improved stability without risk of over dosage of the drug. The present invention also provides oral solution with flavor that has masked bitter taste of muscarinic antagonist. Further, the present invention also provides a process for preparation thereof.

Abstract: The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: The present invention relates to novel liquid compositions and formulations containing a thioureylene compound, a polysaccharide and a liquid vehicle. The compositions and formulations of the invention are useful for dealing with diseases and conditions associated with abnormally high thyroid hormone levels in mammals, such as humans and cats.

Abstract: An oral paste comprising: (i) at least one non-steroidal anti-inflammatory drug; (ii) at least one viscosity modifying agent; and (iii) a liquid vehicle.